Translational research training in oncology requires a mentoring program with components from multiple disciplines. In recent years, there has been a shortage of young investigators with both clinical and laboratory research expertise. In order to increase the pool of talented physician-scientists and Ph.D. scientists in translational cancer research we need to improve training opportunities. The BCM Oncology Scholars Training Program aims to address the needs of both M.D. (or M.D./Ph.D.) and Ph.D. trainees. The program is composed of five scientific research themes including: (1) Omics sciences (genomics, proteomics and metabolomics); (2) Cancer signaling pathways; (3) Stem cells and development; (4) Therapeutics and diagnostics; (5) Cancer epidemiology and prevention. From each class of Baylor hematology/oncology fellows, we will select a scholar and provide three years of research support and mentoring, starting in the second half of the fellowship and extending into the first eighteen months of a junior faculty position. To train Ph.D. the translational research in oncology, we will also select a Ph.D. postdoctoral scholar each year from the BCM postdoctoral pool via open competition and support her/his translational cancer research for three years. Each scholar trainee will receive a training program in oncological research including didactic courses, career development skills and mentored laboratory research. Each trainee will receive mentorship tailored to the specific interests of the trainees. Through co-mentorship for the M.D. and Ph.D. scholars between research mentors and clinical faculty, and a program-specific research seminar series, the proposed T32 will serve as a platform to develop translational cancer collaborative research for our trainees and to nurture their career development.

Public Health Relevance

This proposal aims to train young physicians and researchers so that they can conduct research to improve the diagnosis and treatment for cancer. The training program will equip young investigators with the state-of-the-art knowledge and skills in cancer research. This program will also foster career development of the trainees, and provide critical mentoring and support for the trainees to launch their careers in translational cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA174647-02
Application #
8904628
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
2014-08-05
Project End
2019-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
2
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Kaochar, Salma; Dong, Jianrong; Torres, Marie et al. (2018) ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells. Invest Ophthalmol Vis Sci 59:132-143
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Chang, Elaine; Sabichi, Anita L; Kramer, Jennifer R et al. (2018) Nivolumab Treatment for Cancers in the HIV-infected Population. J Immunother 41:379-383
Krzykawska-Serda, Martyna; Agha, Mahdi S; Ho, Jason Chak-Shing et al. (2018) Chemotherapy and Radiofrequency-Induced Mild Hyperthermia Combined Treatment of Orthotopic Pancreatic Ductal Adenocarcinoma Xenografts. Transl Oncol 11:664-671
Chang, Elaine; Rivero, Gustavo; Patel, Niraj R et al. (2018) HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab. Clin Lymphoma Myeloma Leuk 18:e143-e146
Nair, Amritha; Chung, Hsiang-Ching; Sun, Tingting et al. (2018) Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med 24:505-511
Ware, Matthew J; Nguyen, Lam P; Law, Justin J et al. (2017) A new mild hyperthermia device to treat vascular involvement in cancer surgery. Sci Rep 7:11299
Ware, Matthew J; Krzykawska-Serda, Martyna; Chak-Shing Ho, Jason et al. (2017) Optimizing non-invasive radiofrequency hyperthermia treatment for improving drug delivery in 4T1 mouse breast cancer model. Sci Rep 7:43961
Liu, Kang; Lin, Fang-Tsyr; Graves, Joshua D et al. (2017) Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin. Proc Natl Acad Sci U S A 114:E3766-E3775
Shafaee, Maryam Nemati; Ellis, Matthew James (2017) Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps. J Natl Cancer Inst 109:

Showing the most recent 10 out of 22 publications